

MEP Lung Health Group



# Respiratory Funding

Eva Polverino

European Respiratory Society

February, 2024, Brussels

**#KeepBreathing** 



## **Examples of Respiratory Burdens of Disease**

Disease	Burden	Deaths	Health Years Lost
Asthma	43.5 million	17,000	2 million
COPD	41.3 million	349,000	7.7 million
Lung Cancer	726,000	464,000	10.3 million
Lower Respiratory Tract Infections	947,000	273,000	5.6 million
Tuberculosis	357,000	25,000	990,000
Interstitial Lung Disease	716,000	25,000	496,000
	88 MILLION	1,2 MILLION	27 MILLION

In 2019 in the EU the societal cost for 7 major lung conditions was €422 billion

2019 WHO European Region IRC, Lung Facts - Europe




### Share of total disease burden by cause, World, 2019

Total disease burden, measured in Disability-Adjusted Life Years (DALYs) by sub-category of disease or injury.

DALYs measure the total burden of disease – both from years of life lost due to premature death and years lived with a disability. One DALY equals one lost year of healthy life.

#### **Change country or region**



Note: Non-communicable diseases are shown in blue; communicable, maternal, neonatal and nutritional diseases in red; injuries in grey.



# BREATHE




Europe an ageing population


What does it mean for Lung Health?

### **Cancer with ageing**

## **COPD & asthma with ageing**




NATURE AGING | VOL 2 | MAY 2022 | 365-366 | www.nature.com/nataging




### PNEUMONIA WITH AGEING (invasive pneumococcal disease)



WHO has declared that AMR is one of the top 10 global public health threats facing humanity.







# BREATHE



Pollution and Climate Crisis

Consequences on the Lungs of the EU Population






2019 – "During the past decade several notable viruses have suddenly emerged from obscurity or anonymity to become serious global health threats, provoking concern regarding their sustained epidemic transmission in immunologically naive human populations."

Cell Rep. 2022 Jun 14;39(11):110969. Clin Exp Immunol. 2019 May;196(2):157-166.

rotaviruses

# POLLUTION & CLIMATE CHANGE: What are the consequences for the EU population?





EUROPEAN RESPIRATORY JOURNAL ORIGINAL RESEARCH ARTICLE Z. YU ET AL.

# Associations of improved air quality with lung function growth from childhood to adulthood: the BAMSE study

Zhebin Yu<sup>1</sup>, Simon Kebede Merid<sup>2</sup>, Tom Bellander<sup>1,3</sup>, Anna Bergström<sup>1,3</sup>, Kristina Eneroth<sup>4</sup>, Antonios Georgelis<sup>1,3</sup>, Jenny Hallberg<sup>2,5</sup>, Inger Kull<sup>2,5</sup>, Petter Ljungman<sup>1,6</sup>, Susanna Klevebro<sup>2,5</sup>, Massimo Stafoggia <sup>1,7</sup>, Gang Wang<sup>1,2</sup>, Göran Pershagen<sup>1,3</sup>, Olena Gruzieva <sup>1,3</sup> and Erik Melén <sup>2,5</sup>

## Is this reversible? YES!

TABLE 4 Association between improvement of air quality and differences in lung function growth from age8 to 24 years						
	Unit of improvement in exposure	Raw value		GLI z-score		
		Difference in FEV <sub>1</sub> growth, mL per year (95% CI) <sup>#</sup>	Difference in FVC growth, mL per year (95% CI) <sup>#</sup>	Difference in FEV <sub>1</sub> growth, sp per year (95% CI)	Difference in FVC growth, sp per year (95% CI)	
PM <sub>2.5</sub>	2.19 μg·m <sup>−3</sup>	4.63 (1.64–7.61)	9.38 (4.76–14.00)	0.03 (0.02–0.04)	0.04 (0.03-0.05)	
PM10	1.00 μg·m <sup>−3</sup>	0.72 (-0.91-2.35)	2.77 (0.19-5.35)	0.01 (0.00-0.02)	0.01 (0.01-0.02)	
BC	0.28 μg·m <sup>−3</sup>	2.80 (0.66-4.93)	5.59 (2.30-8.87)	0.02 (0.01-0.03)	0.02 (0.01-0.03)	
NO <sub>x</sub>	6.17 μg·m <sup>−3</sup>	1.70 (-0.16-3.57)	3.29 (0.35–6.23)	0.01 (0.01-0.02)	0.01 (0.01-0.02)	

GLI: Global Lung Initiative; FEV<sub>1</sub>: forced expiratory volume in 1 s; FVC: forced vital capacity; PM<sub>2.5</sub>: particulate matter with diameter  $\leq 10 \mu$ m; BC: black carbon; NO<sub>x</sub>: nitrogen oxides. <sup>#</sup>: estimates were adjusted for age, sex, height, body mass index (BMI) at age 8 years, municipality at birth, parental education level at birth, parental occupation at birth, maternal smoking during pregnancy, environmental tobacco smoke at 8 years, air pollution exposure during the first year of life, BMI at 16 and 24 years, active smoking at 16 and 24 years, and education level at 24 years. Estimates were interpreted as the difference in 1-year growth (95% CI) in FEV<sub>1</sub> and FVC for per unit improvement of air pollution concentrations, with positive values indicating positive associations between improved air quality and increased rate of FEV<sub>1</sub> or FVC growth.

### Reduced air pollution is improving lung function (from 8 to 24 yrs of age)




# LUNG HEALTH: What is the story right now?

INCREASING BURDEN due to

- Ageing
- Effects of climate changes/pollution
- Risk of (viral) pandemics




- for research
- -for prevention and care





## EU4Health 2021-2027

Chronic Respiratory Disease



## 0,1% invested in Chronic Respiratory Disease so far

EU4 Health Budget	5.3 Billion
Chronic Respiratory Disease	5 Million







- The European Council recently adopted a decision, where 1 billion euros (out of 5.3 billion) are to be taken out of the EU4Health Budget
- Given the massive societal burden, funding for respiratory should still continue to be allocated from the remaining funds.
- It is question of political priority.

Yearly Societal Cost of 7 Major Lung Diseases: **€422 billion**